AbVacc, Inc., a recent spin-off of Integrated Biotherapeutics, uses structure-guided rational design for discovery and development of next generation “smart” vaccines and monoclonal antibodies. Funded by US Government grants and Novo Holdings, AbVacc’s portfolio includes vaccines and antibodies for serious emerging infectious diseases such as methicillin resistant S. aureus
(MRSA), C. difficile
, B. anthracis
, filoviruses Ebola, Sudan, and Marburg, Nipah virus, and Influenza at different preclinical stages, and several more candidates in early discovery stage. AbVacc’s MRSA vaccine (IBT-V02), indicated for prevention of recurrent skin and soft tissue infections, is nearing clinical trials with IND filing expected in late 2023.